# 1 Original Research

# 2 Preceding anti-spike IgG levels predicted risk and severity of COVID-19 during the

# 3 Omicron-dominant wave in Santa Fe city, Argentina

- 4 Ayelen T. Eberhardt<sup>1</sup>, Melina Simoncini<sup>2,3</sup>, Carlos Piña<sup>2,3</sup>, Germán Galoppo<sup>4,5</sup>, Virginia Parachú-
- 5 Marco<sup>6</sup>, Andrea Racca<sup>1,7</sup>, Sofía Arce<sup>1</sup>, Evangelina Viotto<sup>2</sup>, Florencia Facelli<sup>1</sup>, Florencia Valli<sup>2</sup>,
- 6 Cecilia Botto<sup>5</sup>, Leonardo Scarpa<sup>2</sup>, Celina Junges<sup>1. 5</sup>, Cintia Palavecino<sup>1</sup>, Camila Beccaria<sup>7,8</sup>, Diego
- 7 Sklar<sup>9</sup>, Graciela Mingo<sup>10</sup>, Alicia Genolet<sup>10</sup>, Mónica Muñoz de Toro<sup>4,5</sup>, Hugo Aimar<sup>9</sup>, Verónica
- 8 Marignac<sup>2,12</sup>, Juan Carlos Bossio<sup>11</sup>, Gustavo Armando<sup>11</sup>, Hugo Fernández<sup>11</sup>, Pablo M.
- 9 Beldomenico<sup>1, 7\*</sup>.
- <sup>1</sup>Laboratorio de Ecología de Enfermedades, Instituto de Ciencias Veterinarias del Litoral (ICIVET-Litoral), Universidad
   Nacional del Litoral Consejo Nacional de Investigaciones Científicas y Técnicas (UNL-CONICET), Esperanza,
- 12 Argentina.
- <sup>2</sup>Centro de Investigación Científica y de Transferencia Tecnológica a la Producción-Consejo Nacional de
   Investigaciones Científicas y Técnicas-Provincia de Entre Ríos-Universidad Autónoma de Entre Ríos, Diamante,
   Argentina.
- 16 <sup>3</sup> Facultad de Ciencia y Tecnología, Universidad Autónoma de Entre Ríos, Diamante, Entre Ríos, Argentina
- 17 <sup>4</sup>Laboratorio de Ecofisiopatología Instituto de Salud y Ambiente del Litoral (ISAL) Universidad Nacional del Litoral-
- 18 Consejo Nacional de Investigaciones Científicas y Técnicas (UNL-CONICET), Santa Fe, Argentina.
- 19 <sup>5</sup>Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral (FBCB-UNL), Santa Fe, Argentina.
- 20 <sup>6</sup>Laboratorio de Ecología Molecular Aplicada, Instituto de Ciencias Veterinarias del Litoral-Universidad Nacional del
- 21 Litoral Consejo Nacional de Investigaciones Científicas y Técnicas (UNL-CONICET), Esperanza, Argentina.
- 22 <sup>7</sup>Facultad de Ciencias Veterinarias, Universidad Nacional del Litoral, Esperanza, Santa Fe, Argentina.
- 23 <sup>8</sup>Laboratorio de Biología Celular y Molecular Aplicada, Instituto de Ciencias Veterinarias Del Litoral (ICIVET-Litoral),
- 24 Universidad Nacional Del Litoral (UNL), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET),
- 25 Esperanza, Santa Fe, Argentina.
- <sup>9</sup>Instituto de Matemáticas Aplicadas del Litoral (IMAL), Universidad Nacional del Litoral Consejo Nacional de
   Investigaciones Científicas y Técnicas (UNL-CONICET), Santa Fe, Argentina.
- <sup>10</sup>Instituto de Estudios Sociales (INES), Universidad Nacional de Entre Ríos-Consejo Nacional de Investigaciones
   Científicas y Técnicas (UNER-CONICET).
- 30 <sup>11</sup>Instituto Nacional de Enfermedades Respiratorias "Dr. Emilio Coni", Santa Fe, Argentina.
- <sup>12</sup>Laboratorio de Investigación en Enfermedades Infecciosas, Dr Néstor Bianchi, Hospital San José de Diamante, Entre
   Ríos, Argentina.
- 33
- 34 \*Correspondence: pbeldome@fcv.unl.edu.ar
- 35

# 36 Abstract

37 The SARS-CoV-2 Omicron variant has increased infectivity and immune escape compared with 38 previous variants, and caused massive COVID-19 waves globally. Despite a vast majority 39 (~90%) of the population of Santa Fe city, Argentina, had been vaccinated and/or had been 40 infected by SARS-CoV-2 by the arrival of Omicron, the epidemic wave that followed was by far 41 the largest one experienced in the city. A serosurvey conducted prior to the arrival of Omicron 42 allowed to assess the acquired humoural defences preceding the wave and to evaluate 43 associations with infection risk and severity during the wave. A very large proportion of the 44 1455 sampled individuals had immunological memory against COVID-19 at the arrival of 45 Omicron (almost 90%), and about half (48.9%) had high anti-Spike IgG levels (>200 UI/mI). The

46 antibody titres were strongly associated with the number of vaccine shots and the vaccine 47 platform received, and also depended markedly on prior COVID-19 diagnosis and the days 48 elapsed since last antigen exposure (vaccine shot or natural infection). Following-up 514 49 participants provided real-world data linking antibody levels with protection against COVID-19 50 during a period of high risk of exposure to an immune-escaping highly transmissible variant. Pre-wave antibody titres were strongly associated with COVID-19 incidence and severity of 51 52 symptoms during the wave. Also, receiving a vaccine shot during the follow-up period reduced 53 the COVID-19 risk drastically (15-fold). These results highlight the importance of maintaining 54 high defences through vaccination anticipating or during a period of high risk of exposure to 55 immune-escaping variants.

56

Keywords: SARS-CoV-2, antibody titre, humoural defences, infection risk, disease severity, longitudinal
 study, pre-exposure

59

# 60 Introduction

As of June 2022, the COVID-19 pandemic continues to occur despite the acquired defences 61 62 developed in a large proportion of people due to vaccination against SARS-CoV-2 and/or 63 natural infection. Several viral variants have evolved, prevailing the ones that achieved 64 enhanced transmissibility and immune escape compared to prior variants (Tian et al. 2022). 65 Until November 2021, some strains had become prominent and had caused new outbreaks 66 worldwide. These were considered variants of concern, and were named Alpha, Beta, Gamma, and Delta. A new variant, B.1.1.529, was first detected in samples collected on 11<sup>th</sup> November 67 2021 in Botswana and on 14<sup>th</sup> November 2021 in South Africa (Tian et al. 2022). On 26<sup>th</sup> 68 November, the WHO defined it as the fifth variant of concern, naming it Omicron. So far, 69 70 Omicron is the variant with the largest number of mutations, many of which provide increased 71 infectivity and immune escape compared with previous variants (Hu et al. 2022; Duong et al. 72 2022). This resulted in massive waves of COVID-19 emerging worldwide soon after the new 73 variant appeared (Daria & Islam, 2022).

74 The dynamics of COVID-19 have been heterogeneous since the beginning of the pandemic 75 (Beldomenico 2020). While countries like United Kingdom and Germany have gone through 76 several epidemic waves, others like Thailand and Vietnam had their first wave only after over a 77 year had passed since SARS-CoV-2 began to circulate in those countries. In Argentina, by early 78 December 2021 there had been two waves, the first one by mid-2020, related to the arrival and spread of the virus, and the second one in 2021 associated with the seasonality of 79 respiratory viruses. Omicron was confirmed in Argentina on 5<sup>th</sup> December 2021, and some 80 81 days later the country suffered the largest COVID-19 epidemic wave so far, with a peak 82 infection rate several times higher than the peaks observed in the two previous waves.

In Santa Fe, a city of around 430,000 inhabitants, COVID-19 dynamics reflected what was
observed elsewhere in the rest of the country (Figure 1). By mid-December 2021, 12.9% of the
citizens had been diagnosed with COVID-19, 90.6% had received a first dose of an anti-SARS-

86 CoV-2 vaccine, 79.2% a second dose, and 10.3% a third one (data provided by the Ministry of 87 Health of Santa Fe province). The wave that followed the arrival of Omicron began around  $18^{h}$ 

December 2022 in Santa Fe city, and the number of daily cases started to decline by mid-88

89 January 2022, returning to levels as low as before the wave by the end of February (Figure 1).

90 During the last two months of 2021, we conducted a survey collecting relevant information on 91 COVID-19 and measuring anti-spike IgG antibodies in people from randomly selected 92 households of Santa Fe city and from citizens that volunteered to participate in the study. This 93 provided the opportunity of characterising the acquired humoural defences of the population 94 of Santa Fe city immediately prior to the arrival of Omicron. In March 2022, after the wave was 95 over, a subset of the study participants were asked to complete a second questionnaire 96 indicating if they were diagnosed with COVID-19 after 15th December 2021, if they got 97 additional vaccine shots, and other relevant information. The data collected allowed us to 98 pursue three goals:

99 1) to describe the acquired humoural immunity of the population immediately prior to 100 the arrival of Omicron

101 2) to assess which factors were associated with such immune status (i.e. previous 102 infection, different vaccination schemes, time from last exposure, etc.), and

103 3) to evaluate if those humoural defences predicted the risk and severity of COVID-19 during the wave. 104



- 107
- 108
- 109
- 110 **Materials and methods**

#### 111 Source of the data

112 A random sample of 1000 households including all neighbourhoods of Santa Fe city was 113 provided by the Instituto Provincial de Estadísticas y Censos. In September and October 2021, 114 those households were visited, and the occupants were invited to participate in a COVID-19 study that involved answering a questionnaire and providing a blood sample to measure IgG 115 antibodies against SARS-CoV-2. A second visit was scheduled from 1<sup>st</sup> November 2021 to 23<sup>rd</sup> 116 December 2021, to fill the questionnaires and take a blood sample. In addition, during that 117 118 period volunteers were invited to participate by announces in the local media. We collected 119 data from 414 people from randomly selected households and 1041 volunteers.

120 The first questionnaire included queries on sex, age, having been diagnosed with COVID-19 121 (with dates and diagnosis details), COVID-19 severity and duration, vaccine shots received 122 (with type and dates), close contacts with COVID-19 cases, co-morbidities, among other 123 information.

Those that were sampled after 15<sup>th</sup> November 2021, were asked to complete a second 124 questionnaire in March 2022. This allowed us to follow the participants from whom there was 125 an antibody measurement within a month prior to the Omicron-dominant wave. The second 126 127 questionnaire inquired for the period that went from the date of the blood sample collection 128 to 28<sup>th</sup> February 2022, and included information on close contact with cases during that 129 period, COVID-19 diagnosis (with dates and diagnosis details), vaccine shots (with type and 130 dates), and disease severity and duration. When there were doubts about the responses given 131 in the questionnaires, the participants were contacted again to ask for clarification. We 132 obtained 514 valid responses to this second questionnaire.

Using the information obtained from the questionnaires, we established a COVID-19 case when the participant indicated that she/he was given positive by the government after an official PCR test, or given positive by the government due to having symptoms while cohabitating with a case, or had a PCR positive test by a private laboratory, or had a positive rapid antigen test while having symptoms or after having had a close contact with a case. People that declared they suspected having had COVID-19 but were not tested (25 in the first questionnaire and 4 in the second questionnaire) were removed from the analysis.

All procedures were carried out under the approval of the Ethics and Biosafety Committee of
 the Scientific and Technological Centre of Santa Fe of the Argentine Council for Research and
 Technology (CCT Santa Fe CONICET). All participants signed an informed consent.

#### 143 **Quantification of IgG**

Levels of anti-SARS-CoV-2 spike protein IgG were quantified by COVID AR IgG immunoassay developed by Instituto Leloir in Argentina (Ojeda et al. 2021), following the manufacturer's instructions. This IgG immunoassay kit consists of a solid phase ELISA that utilizes the trimer of native protein S and a receptor binding domain as antigens, obtained by recombinant DNA techniques produced in human cells.

Briefly, 40 μl of fingertip capillary blood samples were diluted 1:6 in the diluent provided in the
 SEROKIT developed by Instituto Leloir, and kept refrigerated. At the laboratory, samples were

151 re-diluted 1:3, and 200 µl of each 1:18 final dilution were transferred to 96-well plates and incubated at 37°C for one hour. IgG specific for spike protein was captured on the plate, and 152 153 subsequently the wells were thoroughly washed 6 times to remove unbound material. Anti-Human IgG, HRP-linked antibody was then used to recognize the bound IgG. A mix of HRP 154 155 substrate and TMB (1:1) was added to develop color. The magnitude of optical density at 450 nm is proportional to the quantity of IgG specific for spike protein. To estimate antibody levels, 156 157 sample optical densities were converted to concentrations expressed in UI/ml by using a lineal 158 model built with the optical densities (response variables) obtained in each plate from two sets 159 of known dilutions of the positive control at 50, 100, 200 and 400 UI/ml. These dilutions were the independent variable, included as a polynomial term (with lineal and quadratic terms) to 160 address possible non-linearity of the dilution-OD relationship. The  $R^2$  of that model was 161 checked to confirm that the value was >0.85, otherwise all samples were analysed again in a 162 163 new plate.

#### 164 Statistical analysis

165 All statistical analyses were done using the Software R version 4.2.0 (The R Foundation for 166 Statistical Computing). The analyses were conducted in three steps, to pursue three 167 complementary goals, as follows.

168 The first step aimed to characterise the acquired humoural defences in Santa Fe immediately 169 prior to the arrival of Omicron. This part consisted of descriptive statistics of the IgG levels, 170 overall and by age group.

The goal of the second step was to investigate the determinants of the IgG levels measured. 171 172 For this, the antibody levels were the response variable, which were transformed by 173 calculating the square root to approach normality. Two sets of lineal models were run, one containing the polynomial term 'number of doses + (number of doses)<sup>2</sup>' as variable of interest 174 (to take into account possible non-linearity of the titre-dose relationship), and the second set 175 including only the 4 vaccination schemes most frequently observed, to compare antibody 176 levels among them. In both models, the independent variables 'COVID-19' (prior diagnosis of 177 COVID-19) and 'days from last exposure' (vaccine shot or detected infection; whatever 178 179 happened last), were included. The vaccination schemes used for the second model were: two 180 Astra-Zeneca vaccines (viral vector vaccine; N= 411), two Sinopharm (inactivated vaccine; N= 181 334), two Sputnik V vaccines (viral vector vaccine; N= 260), the combination of Spunik V and Moderna (viral vector + mRNA vaccines; N= 155), and two Pfizer/BioNTech (mRNA vaccine; N= 182 183 25).

The third step used information from the second questionnaire to conduct a longitudinal analysis that enabled assessment of how the vaccines and antibody levels influenced the incidence of COVID-19 during the Omicron-dominant wave in Santa Fe. In addition, we looked at associations between antibody levels and COVID-19 symptoms severity and duration among those that were infected during the Omicron-dominant wave. For this third step, the period in which participants were followed to assess new detected infections by SARS-CoV-2 was from December 18<sup>th</sup> to February 28<sup>th</sup> (72 days).

191 In order to establish an association between vaccination status and the incidence of COVID-19 192 during the Omicron-dominant wave, we built a Generalized Lineal Models (GLM) with a 193 binomial response (COVID-19 positive or not). The model used number of vaccine doses as the 194 independent variable of interest, included as a polynomial term.

To assess associations between antibody levels and the incidence of COVID-19 during the 195 196 Omicron-dominant wave, we used a subset of data (N= 484) that excluded participants that 197 got a vaccine shot between 7 days prior of the blood sample collection and 15th December 198 2021 (N= 30), as for those cases the antibody levels recorded did not reflect the humoural 199 immunity on the arrival of Omicron. We built a GLM with a binary response that evaluated 200 associations between antibody levels, while adjusting by a number of relevant factors, detailed 201 below. The independent variable of interest (IgG levels) was also included in a separate model 202 as a dichotomous factor, setting those with antibody levels >400 UI/ml (very high levels; N= 203 158) as 1, and the rest as 0 (N= 326).

204 Finally, in the subset of samples that was diagnosed with COVID-19 during the wave (N= 184) 205 the associations between antibody levels and COVID-19 severity and duration were assessed with ordinal regression models, where the responses were 3-level ordinal variables, as follows. 206 207 Disease severity was measured by asking in the second questionnaire whether they had no or 208 very mild symptoms (e.g. light sore throat, nasal congestion; level 1), mild symptoms (e.g. one 209 or two days of fever and/or light malaise, not requiring bed rest; level 2), or moderate 210 symptoms (e.g. bed rest was required; level 3). The participants were also asked if hospitalization was required, as a  $4^{th}$  level, but none chose this option. As for the duration of 211 212 COVID-19 symptoms (excluding loss of smell), the three levels were: one day or less (level 1), 213 two to five days (level 2), and more than 5 days (level 3).

214 For all models used in step 3, potential confounding phenomena was controlled for by 215 including in the models relevant independent variables, as follows. Age (in years, and assessed 216 separately as a single term or polynomial) was included in all models. Also in all models, 217 receiving a new vaccine during the wave period was included as a two-level independent 218 variable, as those that got a booster shot within the follow-up period had changes in both the antibody levels and the vaccination scheme. The cases in which the vaccine shot was received 219 late in the wave (after 15<sup>th</sup> February 2022; N= 7) were not used in the models that included the 220 221 new shot variable. The number of known close contacts with COVID-19 cases was used as a 222 proxy of exposure, and used for the GLMs assessing associations with COVID-19 incidence. 223 Close contact was defined as being within 3 m distance or indoors for over 15 minutes with 224 someone who was diagnosed with COVID-19, and the contact happened within the period that 225 went from two days prior the onset of symptoms and seven days after the onset of symptoms. 226 The contacts were set at 5 levels, 0, 1, 2, 3, and 4 or more close contacts with cases. Prior 227 COVID-19 was included in models that assessed associations between vaccination status and 228 COVID-19 incidence during the wave. Finally, the presence of co-morbidities (i.e. high blood 229 pressure, diabetes, obesity, heart disease, chronic pulmonary disease, cancer) was included in 230 the models assessing the influence of antibody levels on COVID-19 severity and duration. All 231 these variables used for adjustment purposes were dropped from the models if they were not 232 important for the model's goodness of fit, as indicated by AIC comparisons.

233

### 234 Results

## 235 **Description of the sample**

236 We obtained answers to the first questionnaire and blood samples from 1455 people. Of 237 those, 57.3% were female and 43.7% were male. The mean age was 41 years old, being the 238 minimum 5 months old and the maximum 95 years old.

Almost three quarters (74.7%) of the participants had not been diagnosed with COVID-19 at the time of answering the first questionnaire, but 2.4% of those (N= 25) suspected having been

infected. One quarter (24.8%) was diagnosed with COVID-19 once, and 0.4% (N= 6) twice.

Regarding the vaccination regime, 6.9% of the participants were not vaccinated at the time of sampling, 5% had one dose, 83.6% had two doses, 4.5% had three doses and 0.07% had four doses. The vaccination scheme most frequently applied in the sample was two Astra-Zeneca vaccines, followed by two Sinopharm, two Sputnik V vaccines, and the combination of Spunik V and Moderna. At the time of the sampling, Pfizer/BioNTech vaccines were being used for youngsters aged 13 to 18 years old, having 25 participants of our study two doses, and 19 one dose.

# 249 Characterisation of the acquired humoural defences prior to the Omicron-dominant wave

Anti-spike IgG were detected in 88.7% (1290/1455) of the samples. Among those that received at least one dose of an anti-COVID-19 vaccine, 7.4% (100/1354) did not have detectable IgG. Among the non-vaccinated (N=99), 63.6% (63/99) did not have detectable antibodies. Of the unvaccinated that had antibodies, 72% (26/36) had not been diagnosed with COVID-19 nor suspected having been infected.

255 Almost half (48.9%) of the participants had antibody levels considered to be high (>200 UI/mI), 256 and more than one third (35.4%) had very high levels (>400 UI/ml). The overall mean antibody 257 level was 290 UI/mI, but it varied by age group (Table 1). Among the age group considered to 258 be of high risk (>60 years old), the vast majority was vaccinated (98.1%), but 17% was 259 vulnerable because they had no detectable IgG (6%) or had low antibody levels (11% with <40 260 UI/mI). However, most aged 60 and above had very high antibody levels (65% with >400 261 UI/mI). The high level of antibodies observed in those aged 13-20 is attributable to the good 262 performance of the vaccine received by that age group and the shorter time elapsed from the 263 last shot.

# 264 Antibody levels according to vaccine doses and schemes

Those participants that were not vaccinated had a mean IgG titer of 62.5 UI/ml, while the mean level was 287.9 UI/ml, 293.5 UI/ml, and 567.8 UI/ml for those that received one, two or three doses, respectively. A third dose increased the antibody levels significantly, and there was strong positive association with prior COVID-19 and a strong negative correlation with days that elapsed from last exposure (vaccine or infection) (Figure 2, Table 2).

# 271 Table 1. Central tendency (mean and median) of antibody levels and proportion of vaccine coverage (at

least one shot) by age group, in samples taken from Santa Fe citizens in November and December 2021.

Age range	Sample size	Mean; Median (UI/ml)	% without antibodies	% vaccinated
0-12 years old	84	175; 12	43.4%	47.0%
13-20 years old	87	474; 499	9.0%	85.4%
21-40 years old	535	217; 82	12.2%	95.8%
41-60 years old	438	307; 223	9.5%	96.0%
> 60 years old	311	378; 408	5.9%	98.1%

273

274 Table 2: Lineal model assessing the association between antibody (IgG) levels and number of anti-

275 COVID-19 vaccine doses received, adjusting by prior COVID-19 diagnosis and days from last exposure

276 (vaccine or known infection). Significant terms are printed in bold.

Model = Antibody levels <sup><math>0.5</math></sup> ~ Vaccine doses + Vaccine doses <sup>2</sup> + COVID-19 + Days from	
exposure.	

Term	Coefficients	Standard error	P-value
Intercept	15.6487	1.6665	<0.0001
Vaccine doses	-1.7496	1.5259	0.2518
Vaccine doses <sup>2</sup>	1.2979	0.4477	0.0038
COVID-19	5.0559	0.5401	<0.0001
Days from exposure	-0.0388	0.0036	<0.0001

Antibody levels: Titre of anti-SARS-CoV-2 spike protein lgG.

Vaccine doses: number of vaccine shots received prior to the blood sample.

COVID-19: prior diagnosis of COVID-19.

Days from exposure: days elapsed from the last vaccine shot or detected infection .

#### 277



Figure 2. Levels of antibodies (IgG) against SARS-CoV-2 by number of vaccine doses and prior COVID-19
 diagnosis.

### 281

When comparing the four vaccination schemes most frequently applied while adjusting by prior COVID-19 infection and days elapsed from last exposure, we observed very significant differences in antibody levels (Table 3; Figure 3). The scheme with inactivated vaccines (Sinopharm) showed significantly lower antibody levels than all other schemes, both schemes of viral vectors (Astra-Zeneca and Sputnik V) performed similarly, and the schemes combining vector and mRNA (Sputnik V + Moderna) and two mRNA (Pfizer/BioNTech) showed the highest levels, not statistically different between them (Table 3).

289 Table 3: Lineal model assessing the association between antibody (IgG) levels and different anti-COVID-

290 19 schemes, adjusting by prior COVID-19 diagnosis and days from last exposure (vaccine or known

291 infection). PostHoc Tukey tests indicated the significant differences between vaccination schemes.

292 Significant terms are printed in bold.

Model = Antibody levels <sup>0.5</sup> ~ Vacci	ne schen	ne + COV	D-19 + [	Days from	exposure.		
Term		Coefic	cientes	Stand	dard error	P-value	
Intercept		9	9.5656		0.6366	<0.0001	
Vaccine scheme (AZ+AZ)		-	7.4257		0.5327	<0.0001	
Vaccine scheme (spk+spk)		1	8.7071		0.5917	<0.0001	
Vaccine scheme <sub>(spk+Mod)</sub>		14	4.2388		0.6971	<0.0001	
Vaccine scheme (Pfi+Pfi)		1	7.2906		1.4859	<0.0001	
COVID-19		!	5.5569		0.4686	<0.0001	
Days from exposure		-	0.0315		0.0038	<0.0001	
Multiple Comparisons of Means: Tukey Contrasts							
	Estimate	Std. Error	t value	P-value			
AZ+AZ - Sph+Sph	7.4258	0.5328	13.938	<0.001			
Spk+Spk - Sph+Sph	8.7071	0.5917	14.715	<0.001			
Spk+Mod - Sph+Sph	14.2388	0.6972	20.423	<0.001			
Pfi+Pfi - Sph+Sph	17.2907	1.4860	11.636	<0.001			
Spk+Spk - AZ+AZ	1.2813	0.5698	2.249	0.147			
Spk+Mod - AZ+AZ	6.8130	0.6684	10.193	<0.001			
Pfi+Pfi - AZ+AZ	9.8649	1.4598	6.758	<0.001			
Spk+Mod - Spk+Spk	5.5317	0.7250	7.630	<0.001			
Pfi+Pfi - Spk+Spk	8.5836	1.4962	5.737	<0.001			
Pfi+Pfi - Spk+Mod	3.0518	1.5270	1.999	0.246			
Vaccine scheme: AZ+AZ= Astra Zeneca × 2; Spk+Spk= Sputnik V × 2; Spk+Mod= Sputnik V + Moderna;							
Pfi+Pfi= Pfizer/BioNTech × 2. Reference level: Sph+Sph = Sinopharm × 2.							
Antibody levels: Titre of anti-SARS-CoV-2 spike protein IgG.							
COVID-19: prior diagnosis of COVID-19.							
Days from exposure: days elapsed from the last vaccine shot or detected infection.							



294

Figure 3. Levels of antibodies (IgG) against SARS-CoV-2 by vaccine scheme and prior COVID-19 diagnosis.
 Sph= Sinopharm; AZ= Astra Zeneca; Spk= Sputnik V; Mod= Moderna; Pfi= Pfizer/BioNTech

297

#### 298 Vaccination status and COVID-19 incidence during the Omicron-dominant wave

299 Of the 514 participants followed up during the wave, 184 (35.8%) were diagnosed with COVID-19 between 18<sup>th</sup> December 2022 and 28<sup>th</sup> February 2022. The incidence in those that had had 300 COVID-19 previously was also high (reinfection rate: 39/121 = 32.2%). The number of vaccine 301 302 doses received prior to the arrival of Omicron did not appear to have an effect on the COVID-19 infection risk during the wave (Table 4). However, a deeper analysis taking into account age, 303 304 prior COVID-19, receiving a vaccine dose during the wave, and close contact with cases, showed that the number of doses was significantly associated with infection risk in a non-305 linear way, as observed for the association with antibody levels (Table 2), indicating that a 306 307 significant reduction in infection risk was observed only for those with 3 or more vaccine shots 308 (Table 5). Contact with cases and vaccination during the wave were strong predictors of 309 COVID-19 risk during the wave, and prior COVID-19 was also significantly associated (Table 5).

310

Table 4. COVID-19 attack rate during the Omicron-dominant wave in Santa Fe city, by number of vaccine
 doses received prior to the onset of the wave.

Number of vaccine doses:	0	1	2	3	4	
N=	41	9	405	58	1	
Diagnosed with COVID-19=	15	6	146	17	0	
Attack rate=	36.6%	66.7%	36.0%	29.3%	-	

- **Table 5**. Logistic regression assessing the association between COVID-19 diagnosis (yes/no) during the
- 315 Omicron-dominant wave and number of vaccine doses received before the wave, adjusting by age, prior
- 316 COVID-19, vaccine shot during the wave and number close contacts with cases. Significant terms are
- 317 printed in bold.

Model = COVID-19 (yes/no) ~ Age + Vaccine doses + Vaccine doses <sup>2</sup> + Prior COVID-19 +	
Contact + New vaccine shot	

Term	Coeficientes	Standard error	P-value
Intercept	0.4628	0.0713	<0.0001
Age	-0.0009	0.0011	0.4330
Vaccine doses	0.3299	0.0704	<0.0001
Vaccine doses <sup>2</sup>	-0.1166	0.0229	<0.0001
Prior COVID-19	-0.1050	0.0417	0.0122
Contact	0.0896	0.0212	<0.0001
New vaccine shot	-0.5161	0.0386	<0.0001
Ago: in yoars			

Age: in years.

Vaccine doses: number of vaccine doses received before the wave (0 - 4). Prior COVID-19: diagnosis of COVID-19 before the Omicron-dominant wave. Contact: number close contacts with cases during the Omicron wave. New vaccine shot: vaccine shot during the Omicron wave.

318

### 319 Antibody levels and COVID-19 incidence during the Omicron-dominant wave

320 There was a strong negative association between antibody levels preceding the Omicron-321 dominant wave and COVID-19 incidence during the wave (Figure 4, Table 6 and Table S1). For 322 every 100 UI/ml increase in IgG levels, the risk of infection decreases 12%, adjusting by recent 323 vaccine shot and contact with cases (Table 6). Participants with antibody levels >400 UI/ml at 324 the onset of the wave had 67% less chances of being diagnosed with COVID-19 during the 325 wave (Table S1 in supplementary material). In addition, receiving a vaccine shot after the onset 326 of the wave and the number of close contacts with cases were strong predictors of COVID-19 327 risk in all models. A vaccine shot during the wave reduced 15-fold the probability of COVID-19 328 (Table 6). Every close contact with a case increased 71% the odds of being diagnosed with 329 COVID-19 during the wave (Table 6).

330

- 331 **Table 6**. Logistic regression assessing the association between COVID-19 diagnosis (yes/no) during the
- 332 Omicron-dominant wave and antibody levels, adjusting by vaccine shot during the wave and number
- close contacts with cases. Significant terms are printed in bold.

Model = COVID-19 (yes/no) ~ Ar	ntibody levels + New vaccine	shot + Contact	
Term	Coefficients ( <i>log-odds</i> )	Standard error	P-value
Intercept	0.3857	0.2050	0.0599
Antibody levels	-0.0011	0.0004	0.0062
New vaccine shot	-2.7105	0.2661	<0.0001
Contact	0.5349	0.1419	0.0001
Antibody levels: Titre of anti-SARS-0	CoV-2 spike protein IgG.		

New vaccine shot: vaccine shot during the Omicron wave.

Contact: number of close contacts with cases during the Omicron wave.



335

Figure 4. Predicted probability of COVID-19 during the Omicron-dominant wave depending on the levels
 of antibodies (IgG) against SARS-CoV-2 and the administration of a vaccine dose during the wave. For
 the simulation contact with cases was set at 1.

339

### 340 Antibody levels and COVID-19 severity and duration

The ordinal regression model showed that antibody levels were strongly associated with the severity of the symptoms (Table 7, Figure 5). For every 100 UI/ml increase in the IgG level, the odds of being more likely to have higher disease severity (mild or moderate symptoms versus none or very mild symptoms) decreases 34.8%, holding constant new vaccine shot, age and presence of co-morbidities. The model looking at the association between antibody levels and duration of the symptoms showed a negative trend, but not statistically significant, although borderline (p=0.05; Table S2 in supplementary material).

- 349
- 350
- 351

- 352 **Table 7**. Ordinal regression model assessing the association between severity of COVID-19 symptoms
- and antibody levels, adjusting by vaccine shot during the wave, age and co-morbidities. Significant terms
- are printed in bold.

Model = Severity ~ Antibody levels + New vaccine shot + Age + Co-morbidity.

Term	Coefficients	Standard error	P-value
Antibody levels	-0.0019	0.0005	<0.0001
New vaccine shot	-1.0189	0.4580	0.0261
Age	-0.0089	0.0112	0.4235
Co-morbidity	-0.7914	0.4744	0.0953

Severity: severity of COVID-19 symptoms; 3-level ordinal variable: very mild symptoms, mild symptoms or moderate symptoms.

Antibody levels: Titre of anti-SARS-CoV-2 spike protein IgG.

New vaccine shot: vaccine shot during the Omicron wave.

Age: in years.

Co-morbidity: conditions like high blood pressure, diabetes, obesity, heart disease, chronic pulmonary disease, cancer.





356

Figure 5. Levels of antibodies (IgG) against SARS-CoV-2 at the onset of the Omicron-dominant wave by
 the severity of the symptoms when they became infected during the wave. None or very mild
 symptoms, N= 59; mild disease, N= 69; disease that required bed rest, N= 59.

360

### 361 Discussion

The arrival of the variant Omicron was associated with the largest wave of COVID-19 cases in Santa Fe city (Figure 1), despite immediately prior to the wave a vast majority of the citizens (>90%) had been vaccinated and/or had been infected by SARS-CoV-2. Here we characterised the acquired humoural defences in Santa Fe prior to the arrival of Omicron, estimating that a high proportion of the population had immunological memory against COVID-19 (i.e. almost 90% of our sample had detectable antibodies). Moreover, about half of the participants had

368 high antibody levels (>200 UI/ml). Although the number of cases during the Omicron-dominant wave was much higher than in the previous two waves, the mortality due to COVID-19 was 369 considerably lower. Before the Omicron-dominant wave, there had been 856 deaths over 370 371 55969 cases (case-fatality= 1.5%) in Santa Fe, and during the wave there were 54 deaths over 372 36166 cases (case-fatality= 0.15%) (official records of the Ministry of Health of Santa Fe 373 province). This 10-fold lower impact could be attributable to the high level of defences here 374 described, which is supported by the individual-level data presented, where the severity of 375 COVID-19 was lower the higher the preceding antibody levels. However, because there is 376 evidence that suggests that Omicron may be less pathogenic than previous variants (Ulloa et 377 al. 2022; Wolter et al. 2022) it is difficult to infer how much of the reduced severity is due to 378 immunological experience and how much attributable to virus evolution making new variants 379 less pathogenic (Bhattacharyya et al. 2022).

380 Antibodies provide protection either through direct obstruction of infection or through their 381 ability to leverage the immune system to eliminate pathogens. The neutralising antibody titres 382 generated in vaccine clinical trials are assumed to be correlated with protective effect and the 383 durability of the protection (He et al. 2021). Measuring antibody-mediated protection to 384 coronaviruses requires characterisation of immune responses prior to a known exposure or 385 period of risk. Such data is only available from few human challenge experiments, in which 386 volunteers were exposed to experimental infections with human coronaviruses (Huang et al. 387 2020). Some of those studies showed evidence that pre-exposure titres correlated negatively with infection risk and severity (Bradburne et al. 1967; Callow 1985). More recent relevant 388 389 evidence comes from treatments with convalescent plasma. The efficacy of convalescent 390 plasma transfusion as a treatment for COVID-19 was found to depend on the antibody levels of 391 the plasma. Plasma with higher anti-SARS-CoV-2 IgG antibody levels was associated with a 392 lower risk of death (Joyner et al. 2021). In this longitudinal study, we provide individual-level 393 real-world data linking antibody levels and protection against COVID-19 during a period of high 394 risk of exposure to an immune-escaping highly transmissible variant.

395 We found that the level of antibodies of the participants immediately prior to the arrival of Omicron were strongly associated with the number of vaccine shots and the vaccine platform 396 397 received, and also depended markedly on prior COVID-19 diagnosis and the days elapsed since 398 last exposure (vaccine shot or infection). Those that received a third vaccine dose had much 399 higher antibody levels than participants that got 2 or less shots at the time of sampling, which 400 resulted from the booster effect already documented (Kanokudon et al. 2022). It is noteworthy 401 that in our study this large difference between the titres of 2 and 3 shots was maintained 402 when adjusting by days from the last shot.

403 Another factor that explained the variability in antibody levels in our sample was the 404 vaccination scheme. The vaccine schemes used in Argentina showed different performance in 405 terms of immunogenicity. Two inactivated vaccines (Sinopharm) conferred the lowest antibody 406 levels, and schemes that used mRNA platforms (Sputnik + Moderna or Pfizer/BioNTech × 2) the 407 highest titres, whereas both vector vaccines (Astra Zeneca × 2 or Sputnik V × 2) performed 408 between the other two schemes. This is in agreement with what was reported previously 409 (Banki et al. 2022; Kanokudon et al. 2022; Kudlay & Svistunov 2022).

410 Despite the strong association between vaccination status and antibody levels, an association 411 of the former with COVID-19 incidence during the wave was only apparent when adjusting by 412 age, prior COVID-19, number of close contacts and vaccination during the wave. When all 413 those factors were held equal, only those with 3 doses were found to have lower chances of 414 being diagnosed with COVID-19 during the wave. A recent study showed that the neutralization potency against Omicron was undetectable in sera from most vaccinees, except 415 for individuals recently receiving a RNAm vaccine booster (3<sup>rd</sup> dose) (García-Beltran et al. 416 2022). The apparent lack of effect observed in those with 1 or 2 vaccine doses might result 417 418 from the large variability in immunogenicity of the vaccines used and the strong correlation 419 observed with days elapsed from the last vaccine shot (as those with 3 shots had been 420 vaccinated more recently). It was documented that anti-spike IgG wane quickly (Bayart et al. 421 2021; Levin et al. 2021), and here we confirmed this in a real-world study and showed 422 consequences of waning defences on disease risk and severity.

423 Prior studies have shown increased antibody evasion and greater breakthrough infection risk 424 of Omicron, compared with previous variants (Hoffmann et al. 2021; Mannar et al. 2022; Hu et 425 al. 2022). However, although reduced, the binding of IgG antibodies to the Omicron Spike 426 antigen is maintained, and recent data suggests that extraneutralising antibodies contribute to 427 disease control (Bartsch et al. 2022). This partial immune escape implicates that higher 428 defence levels would be required to reduce the risk and severity of COVID-19 caused by the 429 Omicron variant. Here we present evidence of this in real circumstances. Anti-spike IgG levels 430 and variables that cause antibodies to rise (i.e. prior COVID-19 and a recent boost shot; Table 431 5) were strong drivers of COVID-19 risk and severity. Our results strongly suggest that to 432 reduce the impact of highly transmissible and immune-escaping variants like Omicron, the 433 acquired defences should be kept high. Therefore, booster vaccine shots anticipating or during 434 a period of high exposure risk are highly recommended.

435 The results hereby presented offer an explanation to the epidemiological pattern observed in 436 Santa Fe city during the Omicron-dominant wave. The arrival of the Omicron variant caused 437 the largest COVID-19 epidemic experienced in Santa Fe city since the beginning of the 438 pandemic, but the case-fatality observed was 10-fold lower than that of previous waves. The 439 increased number of cases may be have been caused by the immune escape and high 440 transmissibility of Omicron while the high immune defences existing in the population at the 441 time of its arrival most likely contributed the low impact observed. Disease risk and severity 442 was lowest in individuals with high antibody levels, which highlight the importance of 443 maintaining high defences through vaccination in the presence of immune-escaping variants.

444

#### 445 Acknowledgements

446 This work was funded by the Agencia Santafesina de Ciencia, Tecnología e Innovación (Grant #

447 DEMES-2020-0008). The Instituto Provincial de Estadísticas y Censos of Santa Fe province

448 provided the random sample of households. Laboratorio Lemos, Instituto Leloir, Dr. Andrea

Gamarnik and Dr. Marcelo Yanovsky donated part of the assays used in this work. Special

450 thanks to all participants for accepting taking part in this study. To visit the selected

451 households and collect the samples, we got assistance from Georgina Brusco, Marina Visconti,

- 452 Triana Rodriguez, Shirley Musio, Julieta Maldonado, María Laura Arce, María Belén Marinaro,
- 453 Lucía Slaboch, Lucía Jalit, Camila Maldonado, Florencia Bergogne Cis, Maira Gutierrez, Matías
- 454 Palmero, Karen Mendoza, Antonella Menegazzo, Rocía Gareis, Emiliano Grandoli, Ivana
- 455 Ondarcuhu, Camila Zlauvinen, Damián Doña, María Rocío Bustos, Eduardo Masat and Juliana
- 456 Torancio.
- 457

# 458 References

- 459 Bánki Z, Mateus J, Rössler A, et al. Heterologous ChAdOx1/BNT162b2 vaccination induces
- 460 stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-
- 461 center, three-arm, partially randomized HEVACC trial [published online ahead of print, 2022
- 462 May 23]. *EBioMedicine*. 2022;80:104073. doi:10.1016/j.ebiom.2022.104073.
- Bartsch YC, Tong X, Kang J, et al. Omicron variant Spike-specific antibody binding and Fc
- activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. *Sci Transl Med*.
  2022;14(642):eabn9243. doi:10.1126/scitranslmed.abn9243.
- 466 Bayart JL, Morimont L, Closset M, et al. Confounding Factors Influencing the Kinetics and
- 467 Magnitude of Serological Response Following Administration of BNT162b2. *Microorganisms*.
- 468 2021;9(6):1340. Published 2021 Jun 21. doi:10.3390/microorganisms9061340.
- 469 Bhattacharyya RP, Hanage WP. Challenges in Inferring Intrinsic Severity of the SARS-CoV-2
- 470 Omicron Variant. *N Engl J Med*. 2022;386(7):e14. doi:10.1056/NEJMp2119682.
- 471 Bradburne AF, Bynoe ML, Tyrrell DA. Effects of a "new" human respiratory virus in
- 472 volunteers. *Br Med J*. 1967;3(5568):767-769. doi:10.1136/bmj.3.5568.767.
- 473 Beldomenico PM. Do superspreaders generate new superspreaders? A hypothesis to explain
- the propagation pattern of COVID-19. *Int J Infect Dis.* 2020;96:461-463.
- 475 doi:10.1016/j.ijid.2020.05.025.
- 476 Callow KA. Effect of specific humoral immunity and some non-specific factors on resistance of
- 477 volunteers to respiratory coronavirus infection. *J Hyg (Lond)*. 1985;95(1):173-189.
- 478 doi:10.1017/s0022172400062410.
- Daria S, Islam MR. The SARS-CoV-2 omicron wave is indicating the end of the pandemic phase
  but the COVID-19 will continue. *J Med Virol*. 2022;94(6):2343-2345. doi:10.1002/jmv.27635.
- 481 Duong BV, Larpruenrudee P, Fang T, et al. Is the SARS CoV-2 Omicron Variant Deadlier and
- 482 More Transmissible Than Delta Variant?. *Int J Environ Res Public Health*. 2022;19(8):4586.
- 483 Published 2022 Apr 11. doi:10.3390/ijerph19084586.
- 484 Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters
- 485 induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell*. 2022;185(3):457-
- 486 466.e4. doi:10.1016/j.cell.2021.12.033.

- 487 He Q, Mao Q, Zhang J, et al. COVID-19 Vaccines: Current Understanding on Immunogenicity,
- 488 Safety, and Further Considerations. *Front Immunol*. 2021;12:669339. Published 2021 Apr 12.
- 489 doi:10.3389/fimmu.2021.669339.
- 490 Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-
- 491 mediated neutralization: Implications for control of the COVID-19 pandemic. *Cell*.
- 492 2022;185(3):447-456.e11. doi:10.1016/j.cell.2021.12.032.
- Hu J, Peng P, Cao X, et al. Increased immune escape of the new SARS-CoV-2 variant of concern
  Omicron. *Cell Mol Immunol*. 2022;19(2):293-295. doi:10.1038/s41423-021-00836-z.
- 495 Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated
- 496 immunity to coronaviruses: kinetics, correlates of protection, and association with
- 497 severity. *Nat Commun*. 2020;11(1):4704. Published 2020 Sep 17. doi:10.1038/s41467-020-
- 498 18450-4.
- Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent Plasma Antibody Levels and the Risk of
  Death from Covid-19. *N Engl J Med*. 2021;384(11):1015-1027. doi:10.1056/NEJMoa2031893.
- 501 Kanokudom S, Assawakosri S, Suntronwong N, et al. Safety and Immunogenicity of the Third

502 Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized

Healthy Adults with Inactivated Vaccine. *Vaccines (Basel)*. 2022;10(1):86. Published 2022 Jan 6.
doi:10.3390/vaccines10010086.

- 505 Kudlay D, Svistunov A. COVID-19 Vaccines: An Overview of Different Platforms. *Bioengineering* 506 (*Basel*). 2022;9(2):72. Published 2022 Feb 12. doi:10.3390/bioengineering9020072.
- Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19
  Vaccine over 6 Months. *N Engl J Med*. 2021;385(24):e84. doi:10.1056/NEJMoa2114583.
- 509 Mannar D, Saville JW, Zhu X, et al. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM

510 structure of spike protein-ACE2 complex. *Science*. 2022;375(6582):760-764.

- 511 doi:10.1126/science.abn7760.
- 512 Ojeda DS, Gonzalez Lopez Ledesma MM, Pallarés HM, et al. Emergency response for evaluating
- 513 SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. *PLoS*
- 514 *Pathog.* 2021;17(1):e1009161. Published 2021 Jan 14. doi:10.1371/journal.ppat.1009161.
- 515Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the highly mutated516SARS-CoV-2 Omicron variant. J Med Virol. 2022;94(6):2376-2383. doi:10.1002/jmv.27643.
- 517 Ulloa AC, Buchan SA, Daneman N, Brown KA. Estimates of SARS-CoV-2 Omicron Variant
- 518 Severity in Ontario, Canada. JAMA. 2022;327(13):1286-1288. doi:10.1001/jama.2022.2274.
- 519 Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2
- 520 omicron variant in South Africa: a data linkage study. *Lancet*. 2022;399(10323):437-446.
- 521 doi:10.1016/S0140-6736(22)00017-4.